{
    "clinical_study": {
        "@rank": "33752", 
        "arm_group": [
            {
                "arm_group_label": "Phase I: 0.08 mg/kg", 
                "arm_group_type": "Experimental", 
                "description": "Escalating dose groups: 0.08 mg/kg PF-3512676 Injection"
            }, 
            {
                "arm_group_label": "Phase I: 0.16 mg/kg", 
                "arm_group_type": "Experimental", 
                "description": "Escalating dose groups: 0.16 mg/kg PF-3512676 Injection"
            }, 
            {
                "arm_group_label": "Phase I: 0.24 mg/kg", 
                "arm_group_type": "Experimental", 
                "description": "Escalating dose groups: 0.24 mg/kg PF-3512676 Injection"
            }, 
            {
                "arm_group_label": "Phase I: 0.28 mg/kg", 
                "arm_group_type": "Experimental", 
                "description": "Escalating dose groups: 0.28 mg/kg PF-3512676 Injection"
            }, 
            {
                "arm_group_label": "Phase I: 0.32 mg/kg", 
                "arm_group_type": "Experimental", 
                "description": "Escalating dose groups: 0.32 mg/kg PF-3512676 Injection"
            }, 
            {
                "arm_group_label": "Phase I: 0.36 mg/kg", 
                "arm_group_type": "Experimental", 
                "description": "Escalating dose groups: 0.36 mg/kg PF-3512676 Injection"
            }, 
            {
                "arm_group_label": "Phase II: 10 mg", 
                "arm_group_type": "Experimental", 
                "description": "Phase II: 10 mg flat dose (random assignment in Phase II)"
            }, 
            {
                "arm_group_label": "Phase II: 25 mg", 
                "arm_group_type": "Experimental", 
                "description": "Weekly subcutaneous injections of 25 mg PF-3512676.  Treatment continues for a minimum of 8 weeks unless disease progression or unacceptable toxicity occurs, or a maximum of 24 weeks."
            }
        ], 
        "brief_summary": {
            "textblock": "To assess the effect of CPG 7909 Injection on Cutaneous T-cell lymphoma and the safety of\n      CPG 7909 Injection in patients with this cancer."
        }, 
        "brief_title": "CPG 7909 in Patients With Cutaneous T-Cell Lymphoma", 
        "completion_date": {
            "#text": "March 2007", 
            "@type": "Actual"
        }, 
        "condition": "Lymphoma, T-Cell, Cutaneous", 
        "condition_browse": {
            "mesh_term": [
                "Lymphoma", 
                "Lymphoma, T-Cell", 
                "Lymphoma, T-Cell, Cutaneous"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Patients 18 years or older with biopsy (histopathologically) confirmed cutaneous T-cell\n        lymphoma (limited to mycosis fungoides (MF)) who have had prior therapy with at least one\n        and no more than 3 systemic treatments.\n\n        Exclusion Criteria:\n\n        Patients with visceral involvement, serious infection or illness including human\n        immunodeficiency virus infection, or a Karnofsky Performance Status (KPS) < 60 will be\n        excluded."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "42", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 8, 2002", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_alias": "NCT00091208", 
            "nct_id": "NCT00043420", 
            "org_study_id": "C014", 
            "secondary_id": "CO14, A8501014"
        }, 
        "intervention": [
            {
                "arm_group_label": "Phase I: 0.08 mg/kg", 
                "description": "Weekly subcutaneous injections of 0.08mg/kg PF-3512676.  Treatment continues for a minimum of 8 weeks unless disease progression or unacceptable toxicity occurs, or a maximum of 24 weeks.", 
                "intervention_name": "PF-3512676", 
                "intervention_type": "Drug", 
                "other_name": "ProMune, CPG 7909"
            }, 
            {
                "arm_group_label": "Phase I: 0.16 mg/kg", 
                "description": "Weekly subcutaneous injections of 0.16mg/kg PF-3512676.  Treatment continues for a minimum of 8 weeks unless disease progression or unacceptable toxicity occurs, or a maximum of 24 weeks.", 
                "intervention_name": "PF-3512676", 
                "intervention_type": "Drug", 
                "other_name": "ProMune, CPG 7909"
            }, 
            {
                "arm_group_label": "Phase I: 0.24 mg/kg", 
                "description": "Weekly subcutaneous injections of 0.24mg/kg PF-3512676.  Treatment continues for a minimum of 8 weeks unless disease progression or unacceptable toxicity occurs, or a maximum of 24 weeks.", 
                "intervention_name": "PF-3512676", 
                "intervention_type": "Drug", 
                "other_name": "ProMune, CPG 7909"
            }, 
            {
                "arm_group_label": "Phase I: 0.28 mg/kg", 
                "description": "Weekly subcutaneous injections of 0.28mg/kg PF-3512676.  Treatment continues for a minimum of 8 weeks unless disease progression or unacceptable toxicity occurs, or a maximum of 24 weeks.", 
                "intervention_name": "PF-3512676", 
                "intervention_type": "Drug", 
                "other_name": "ProMune, CPG 7909"
            }, 
            {
                "arm_group_label": "Phase I: 0.32 mg/kg", 
                "description": "Weekly subcutaneous injections of 0.32mg/kg PF-3512676.  Treatment continues for a minimum of 8 weeks unless disease progression or unacceptable toxicity occurs, or a maximum of 24 weeks.", 
                "intervention_name": "PF-3512676", 
                "intervention_type": "Drug", 
                "other_name": "ProMune, CPG 7909"
            }, 
            {
                "arm_group_label": "Phase I: 0.36 mg/kg", 
                "description": "Weekly subcutaneous injections of 0.36mg/kg PF-3512676.  Treatment continues for a minimum of 8 weeks unless disease progression or unacceptable toxicity occurs, or a maximum of 24 weeks.", 
                "intervention_name": "PF-3512676", 
                "intervention_type": "Drug", 
                "other_name": "ProMune, CPG 7909"
            }, 
            {
                "arm_group_label": "Phase II: 10 mg", 
                "description": "Weekly subcutaneous injections of 10 mg PF-3512676.  Treatment continues for a minimum of 8 weeks unless disease progression or unacceptable toxicity occurs, or a maximum of 24 weeks.", 
                "intervention_name": "PF-3512676", 
                "intervention_type": "Drug", 
                "other_name": "ProMune, CPG 7909"
            }, 
            {
                "arm_group_label": "Phase II: 25 mg", 
                "description": "Weekly subcutaneous injections of 25 mg PF-3512676.  Treatment continues for a minimum of 8 weeks unless disease progression or unacceptable toxicity occurs, or a maximum of 24 weeks.", 
                "intervention_name": "PF-3512676", 
                "intervention_type": "Drug", 
                "other_name": "ProMune, CPG 7909"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": "immunotherapy, lymphoma", 
        "lastchanged_date": "February 11, 2009", 
        "link": {
            "description": "To obtain contact information for a study center near you, click here.", 
            "url": "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=CO14&StudyName=CPG%207909%20in%20Patients%20With%20Cutaneous%20T-Cell%20Lymphoma"
        }, 
        "number_of_arms": "8", 
        "official_title": "A Phase I/II Open Label, Multi-Center Study For The Evaluation Of Pf-3512676 (CPG 7909) In Patients With Stage Ib To Iva Cutaneous T-Cell Lymphoma", 
        "overall_official": {
            "affiliation": "Pfizer", 
            "last_name": "Pfizer CT.gov Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "March 2007", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Safety: Adverse events, vital signs, clinical and laboratory parameters, physical exams, and ECGs", 
                "safety_issue": "Yes", 
                "time_frame": "24 weeks"
            }, 
            {
                "measure": "Efficacy: Evaluate tumor response as measured by the Composite Assessment of Index Lesion Disease Severity (CA). The primary endpoint will be the overall tumor response rate as assessed by the CA.", 
                "safety_issue": "No", 
                "time_frame": "24 weeks"
            }
        ], 
        "removed_countries": {
            "country": "United States"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00043420"
        }, 
        "responsible_party": {
            "name_title": "Director, Clinical Trial Disclosure Group", 
            "organization": "Pfizer, Inc."
        }, 
        "secondary_outcome": {
            "measure": "Secondary efficacy endpoints include disease response assessed by the PGA, duration of overall response, duration of CCR, duration of PR, time to response and time to progression of disease.", 
            "time_frame": "indeterminate"
        }, 
        "source": "Pfizer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2003", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2009"
    }, 
    "geocoordinates": {}
}